Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections-Reference-Cited by-同舟云学术

Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections

Published:2020-04-21 Issue:5 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Ackley Renee¹,Roshdy Danya¹,Meredith Jacqueline¹,Minor Sarah²,Anderson William E.³,Capraro Gerald A.⁴,Polk Christopher⁵

Affiliation:

1. Department of Pharmacy, Atrium Health, Charlotte, North Carolina, USA

2. Department of Pharmacy, AdventHealth, Orlando, Florida, USA

3. Center for Outcomes Research and Evaluation, Charlotte, North Carolina, USA

4. Carolinas Pathology, Atrium Health Clinical Microbiology Laboratory, Charlotte, North Carolina, USA

5. Department of Internal Medicine, Division of Infectious Diseases, Atrium Health, Charlotte, North Carolina, USA

Abstract

The comparative efficacy of ceftazidime-avibactam and meropenem-vaborbactam for treatment of carbapenem-resistant Enterobacteriaceae (CRE) infections remains unknown. This was a multicenter, retrospective cohort study of adults with CRE infections who received ceftazidime-avibactam or meropenem-vaborbactam for ≥72 hours from February 2015 to October 2018. Patients with a localized urinary tract infection and repeat study drug exposures after the first episode were excluded.

Funder

Melinta Therapeutics, Inc.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02313-19

Reference29 articles.

1. Centers for Disease Control and Prevention (CDC). 2019. Antibiotic resistance threats in the United States 2019. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf.

2. Multicenter Clinical and Molecular Epidemiological Analysis of Bacteremia Due to Carbapenem-Resistant Enterobacteriaceae (CRE) in the CRE Epicenter of the United States

3. Surveillance of Carbapenem-Resistant Klebsiella pneumoniae: Tracking Molecular Epidemiology and Outcomes through a Regional Network

4. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes

5. Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections

Cited by 117 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic Review and Meta-Analysis of Clinical Efficacy and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections;International Journal of Molecular Sciences;2024-09-04

2. Ceftazidime/avibactam alone or in combination with an aminoglycoside for treatment of carbapenem-resistant Enterobacterales infections: a retrospective cohort study;International Journal of Antimicrobial Agents;2024-09

3. Ceftazidime-avibactam: Combination therapy versus monotherapy in the challenge of pneumonia caused by carbapenem-resistant Klebsiella pneumoniae;Heliyon;2024-08

4. Screening of Intensive Care Unit Patients for the Presence of Carbapenem-resistant Enterobacterales (CRE) on Admission as a Measure of Infection Control;Journal of Pure and Applied Microbiology;2024-07-31

5. Novel Antibiotics for Gram-Negative Nosocomial Pneumonia;Antibiotics;2024-07-05